Resistant or difficult-to-control hypertension

New England Journal of Medicine

Volumn 355, Issue 4, 2006, Pages 385-392

  Moser, Marvin ^a   Setaro, John F ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CYCLOOXYGENASE 2 INHIBITOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; IBUPROFEN; LISINOPRIL; LOOP DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; THIAZIDE DIURETIC AGENT; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

AGED; ANAMNESIS; ARTICLE; BLOOD PRESSURE MEASUREMENT; CASE REPORT; CREATININE BLOOD LEVEL; DIASTOLIC BLOOD PRESSURE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; LABORATORY TEST; MEDICAL ASSESSMENT; OPHTHALMOSCOPY; OSTEOARTHRITIS; PATIENT COMPLIANCE; PHYSICAL EXAMINATION; POTASSIUM BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULSE RATE; SYSTOLIC BLOOD PRESSURE; TREATMENT REFUSAL; DRUG COMBINATION; DRUG RESISTANCE; MULTIMODALITY CANCER THERAPY; REVIEW; SODIUM RESTRICTION;

AGED; ANTIHYPERTENSIVE AGENTS; COMBINED MODALITY THERAPY; DIET, SODIUM-RESTRICTED; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; PATIENT COMPLIANCE; PRACTICE GUIDELINES;

EID: 33746430561     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp041698     Document Type: Article

References (37)

1. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289:2560-72. [Erratum, JAMA 2003;290:197.]
2. ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:1981-97. [Errata, JAMA 2003;289:178, 2004;291:2196.]
3. Black HR, Elliott WJ, Grandits G, et al. Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA 2003;289:2073-82.
4. Singer GM, Izhar M, Black HR. Goal-oriented hypertension management: translating clinical trials to practice. Hypertension 2002;40:464-9.
5. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001;345:479-86. [Erratum, N Engl J Med 2002;346:544.]
6. Cuspidi C, Macca G, Sampieri L, et al. High prevalence of cardiac and extracardiac organ damage in refractory hypertension. J Hypertens 2001;19:2063-70.
7. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003;290:199-206.
8. Setaro JF, Black HR. Refractory hypertension. N Engl J Med 1992;327:543-7.
9. Omvik P. How smoking affects blood pressure. Blood Press 1996;5:71-7.
10. Jee SH, He J, Whelton PK, Suh I, Klag MJ. The effect of chronic coffee drinking on blood pressure: a meta-analysis of controlled clinical trials. Hypertension 1999;33:647-52.
11. Wofford MR, King DS, Wyatt SB, Jones DW. Secondary hypertension: detection and management for the primary care provider. J Clin Hypertens (Greenwich) 2000;2:124-31.
12. Graves JW, Bloomfild RL, Buckalew VM Jr. Plasma volume in resistant hypertension: guide to pathophysiology and therapy. Am J Med Sci 1989;298:361-5.
13. Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner HR. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19:335-41.
14. Veglio F, Rabbia F, Riva P, et al. Ambulatory blood pressure monitoring and clinical characteristics of the true and white-coat resistant hypertension. Clin Exp Hypertens 2001;23:203-11.
15. Staessen JA, Hond ED, Celis H, et al. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office: a randomized controlled trial. JAMA 2004;291:955-64.
16. Messerli FH, Ventura HO, Amodeo C. Osler's maneuver and pseudo-hypertension. N Engl J Med 1985;312:1548-51.
17. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998;339:1957-63
18. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens 2005;18:619-26.
19. Sowers JR, White WB, Pitt B, et al. The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus. Arch Intern Med 2005;165:161-8. [Erratum, Arch Intern Med 2005;165:551.]
20. Whelton A, Fort JG, Puma JA, Normandin D, Bello AE, Verburg KM. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001;8:85-95. [Erratum, Am J Ther 2001;8:220.]
21. Xin X, He J, Frontini MG, Ogden LG, Motsamai OI, Whelton PK. Effects of alcohol reduction on blood pressure: a meta-analysis of randomized controlled trials. Hypertension 2001;38:1112-7.
22. Weinberger MH. Salt sensitivity of blood pressure in humans. Hypertension 1996;27:481-90.
23. Bramlage P, Pittrow D, Wittchen HU, et al. Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 2004;17:904-10.
24. Modan M, Almog S, Fuchs Z, Chetrit A, Lusky A, Halkin H. Obesity, glucose intolerance, hyperinsulinemia, and response to antihypertensive drugs. Hypertension 1991;17:565-73.
25. Anderson GH Jr, Blakeman N, Streeten DH. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994;12:609-15.
26. Van Jaarsveld B, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal artery stenosis. N Engl J Med 2000;342:1007-14.
27. Nishizaka MK, Calhoun DA. Use of aldosterone antagonists in resistant hypertension. J Clin Hypertens (Greenwich) 2004;6:458-60.
28. Logan AG, Perlikowski SM, Mente A, et al. High prevalence of unrecognized sleep apnoea in drug-resistant hypertension. J Hypertens 2001;19:2271-7.
29. Pepperell JC, Ramdassingh-Dow S, Costhwaite N, et al. Ambulatory blood pressure after therapeutic and subtherapeutic nasal continuous positive airway pressure for obstructive sleep apnea: a randomised parallel trial. Lancet 2002;359:204-10.
30. Kaplan NM. Clinical hypertension. Baltimore: Williams & Wilkins, 1998.
31. Hill MN, Miller NH. Compliance enhancement: a call for multidisciplinary team approaches. Circulation 1996;93:4-6.
32. Moser M, Prisant LM. Low-dose combination therapy in hypertension. Am Fam Physician 1997;56:1275-6, 1279, 1282.
33. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: comparing hemodynamic management to specialist care. Hypertension 2002;39:982-8.
34. Finnerty FA, Maxwell MH, Lunn J, Moser M. Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension: a two-year comparison of efficacy and safety. Angiology 1977;28:125-33.
35. Saseen JJ, Carter BL, Brown TE, Elliott WJ, Black HR. Comparison of nifedipine alone and with diltiazem or verapamil in hypertension. Hypertension 1996;28:109-14.
36. Mogensen CE, Neldam S, Takkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the Candesartan and Lisinopril Microalbuminuria (CALM) Study. BMJ 2000;321:1440-4.
37. O'Rorke JE, Richardson WS. Evidence based management of hypertension: what to do when blood pressure is difficult to control. BMJ 2001;322:1229-32.